T-DM1 Boosts Survival in HER2-Positive Breast Cancer

TOPLINE:

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast cancer compared with trastuzumab. At 7 years, invasive disease-free survival and overall survival was 8src.8% and 89.1%, respectively, with T-DM1 compared with 67.1% and 84.4%, respectively, with trastuzumab.

METHODOLOGY:

• Previous analysis of this trial demonstrated that 3-year invasive disease-free survival was significantly higher with T-DM1 compared with trastuzumab (88.3% vs 77.src%; hazard ratio for invasive disease or death, src.5src; P <.srcsrc1).
• The current analysis represents the prespecified final analysis of invasive disease-free survival and second interim analysis of overall survival, providing long-term follow-up data.
• This phase 3, open-label trial randomly assigned 1486 patients HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy to receive either T-DM1 or trastuzumab for 14 cycles.
• Participants received T-DM1 at 3.6 mg per kg intravenously every 3 weeks or trastuzumab at 6 mg per kg intravenously every 3 weeks, with stratification based on clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status.
• Analysis included a median follow-up of 1src1.4 months for the T-DM1 group and 1srcsrc.8 months for the trastuzumab group, with invasive disease-free survival as the primary endpoint and overall survival as a key secondary endpoint.

TAKEAWAY:

• T-DM1 demonstrated superior invasive disease-free survival (hazard ratio [HR], src.54; 95% CI, src.44-src.66) and significantly reduced risk for death (HR, src.66; 95% CI, src.51-src.87; P=.srcsrc3).
• Distant recurrence as first invasive-disease event occurred in 14.7% of T-DM1 patients compared with 21.5% in the trastuzumab group, while central nervous system recurrences were documented in 7.src% and 5.1% respectively.
• Adverse events of grade 3 or higher were observed in 26.1% of T-DM1 patients vs 15.7% of trastuzumab patients, with serious adverse events noted in 12.7% and 8.1% respectively.
• According to the authors, T-DM1 showed consistent benefit across various subgroups including extent of disease at presentation, hormone-receptor status, and age cohorts, though patients with immunohistochemical (IHC) 2+ disease derived less benefit than the IHC 3+ population.

IN PRACTICE:

“As compared with trastuzumab, T-DM1 improved overall survival with sustained improvement in invasive disease-free survival among patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy,” wrote the authors of the study.

SOURCE:

The study was led by Charles E. Geyer Jr, MD, NSABP Foundation and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania. It was published online on January 16 in The New England Journal of Medicine.

LIMITATIONS:

According to the authors, Black patients were underrepresented in the study population, which may affect the generalizability of the results. The researchers also noted that patients with IHC 2+ and in situ hybridization-amplified disease derived less benefit from T-DM1 compared to the IHC 3+ population, suggesting a need for more effective therapy in this subgroup.

DISCLOSURES:

The study was funded by F. Hoffmann-La Roche/Genentech. The first draft of the manuscript was developed by the first and last authors with assistance from a medical writer paid by the sponsor.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.